METTL3-Regulated lncRNA SNHG7 Drives MNNG-Induced Epithelial–Mesenchymal Transition in Gastric Precancerous Lesions
Toxics · 06.08.2024 · 12 (8) · 573
DOI: 10.3390/toxics12080573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxics, online erschienen am 06.08.2024. Verfasst von Jiabei Jian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Occupational Health and Environmental Health, School of Public Health, Lanzhou University, Lanzhou 730000, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds, Medical Innovation and Development Project of Lanzhou University, Key Research and Development Plan (Social Development) Project of Jiangsu Province.
Abstract (Originalsprache)
As a representative item of chemical carcinogen, MNNG is closely associated with the onset of gastric cancer (GC), where N6-methyladonosine (m6A) RNA methylation is recognized as a critical epigenetic event. In our previous study, we found that the m6A modification by methyltransferase METTL3 was up-regulated in MNNG-exposed malignant GES-1 cells (MC cells) compared to control cells in vitro, and long non-coding RNA SNHG7 as a downstream target of the METTL3. However, the functional role of METTL3 in mediating the SNHG7 axis in MNNG-induced GC remains unclear. In the present study, we continuously investigate the functional role of METTL3 in mediating the SNHG7 axis in MNNG-induced GC. RIP-PCR and m6A-IP-qPCR were used to examine the molecular mechanism underlying the METTL3/m6A/SNHG7 axis in MNNG-induced GC. A METTL3 knockout mice model was constructed and exposed by MNNG. Western blot analysis, IHC analysis, and RT-qPCR were used to measure the expression of METTL3, SNHG7, and EMT markers. In this study, we demonstrated that in MNNG-induced GC tumorigenesis, the m6A modification regulator METTL3 facilitates cellular EMT and biological functions through the m6A/SNHG7 axis using in vitro and in vivo models. In conclusion, our study provides novel insights into critical epigenetic molecular events vital to MNNG-induced gastric carcinogenesis. These findings suggest the potential therapeutic targets of METTL3 for GC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Occupational Health and Environmental Health, School of Public Health, Lanzhou University, Lanzhou 730000, China.
- Qinghai Provincial Center for Disease Control and Prevention, Institute of Immunization Planning, Xining 810000, China.
- Gansu Provincial Center for Disease Prevention and Control, Lanzhou 730000, China.
- Department of Toxicology, School of Public Health, Lanzhou University, Lanzhou 730000, China.
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210096, China.
Förderung
- Fundamental Research Funds
- Medical Innovation and Development Project of Lanzhou University
- Key Research and Development Plan (Social Development) Project of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Jian, J., Feng, Y., Wang, R., Li, C., Zhang, L., Ruan, Y., Luo, B., Liang, G., & Liu, T. (2024). METTL3-Regulated lncRNA SNHG7 Drives MNNG-Induced Epithelial–Mesenchymal Transition in Gastric Precancerous Lesions. Toxics, 12(8), 573. https://doi.org/10.3390/toxics12080573
Vancouver
Jian J, Feng Y, Wang R, Li C, Zhang L, Ruan Y, et al. METTL3-Regulated lncRNA SNHG7 Drives MNNG-Induced Epithelial–Mesenchymal Transition in Gastric Precancerous Lesions. Toxics. 2024;12(8):573. doi:10.3390/toxics12080573
BibTeX
@article{Jian2024,
author = {Jian, Jiabei and Feng, Yanlu and Wang, Ruiying and Li, Chengyun and Zhang, Lin and Ruan, Ye and Luo, Bin and Liang, Geyu and Liu, Tong},
title = {METTL3-Regulated lncRNA SNHG7 Drives MNNG-Induced Epithelial–Mesenchymal Transition in Gastric Precancerous Lesions},
journal = {Toxics},
year = {2024},
volume = {12},
number = {8},
pages = {573},
doi = {10.3390/toxics12080573}
}
EUVIMED